

Accepted Manuscript

Efficacy of Granulocyte Colony Stimulating Factor and N-acetyl Cysteine Therapies in Patients with Severe Alcoholic Hepatitis

Virendra Singh, Amarjit Keisham, Ashish Bhalla, Navneet Sharma, Ritesh Agarwal, Ratiram Sharma, Akash Singh



PII: S1542-3565(18)30110-1
DOI: [10.1016/j.cgh.2018.01.040](https://doi.org/10.1016/j.cgh.2018.01.040)
Reference: YJCGH 55676

To appear in: *Clinical Gastroenterology and Hepatology*
Accepted Date: 21 January 2018

Please cite this article as: Singh V, Keisham A, Bhalla A, Sharma N, Agarwal R, Sharma R, Singh A, Efficacy of Granulocyte Colony Stimulating Factor and N-acetyl Cysteine Therapies in Patients with Severe Alcoholic Hepatitis, *Clinical Gastroenterology and Hepatology* (2018), doi: 10.1016/j.cgh.2018.01.040.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Efficacy of Granulocyte Colony Stimulating Factor and N-acetyl Cysteine Therapies in Patients with Severe Alcoholic Hepatitis

(Short title: G-CSF and NAC in alcoholic hepatitis)

Virendra Singh,¹ Amarjit Keisham,² Ashish Bhalla,² Navneet Sharma,² Ritesh Agarwal,³ Ratiram Sharma,⁴ Akash Singh¹

Departments of ¹Hepatology, ²Internal Medicine, ³Pulmonary Medicine and ⁴Transfusion Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh (INDIA)

Guarantor of the article: Virendra Singh, M.D., D.M.

Specific author contributions: Virendra Singh: development of the protocol and the study, patient enrollment and follow-up, and manuscript writing and data analysis; Amarjit Keisham: patient enrollment and follow-up, data collection and analysis, and statistical calculations; Navneet Sharma, and Ashish Bhalla: patient enrollment; Ratiram Sharma: estimation of CD34+cells; Ritesh Agarwal: manuscript writing and statistical calculations; Akash Singh: manuscript writing and statistical calculations.

Financial support: The authors who have taken part in this study declare that partial funding was done for conducting this trial by the society for the study of liver diseases.

Potential competing interests: None.

Abbreviations:

AH: Alcoholic hepatitis
ACLF: acute-on-chronic liver failure
ALT: alanine aminotransferase
AST: aspartate aminotransferase;
G-CSF: Granulocyte colony stimulating factor
CD34: Stem cell marker
CTP: Child-Turcotte-Pugh score
MELD: Model for end stage liver disease
mDF: modified discriminant function
NAC: N-Acetyl Cysteine

Acknowledgments: This trial is registered with ClinicalTrials.gov (NCT02971306). Part of the paper presented as a late breaking abstract-oral session at The Liver Meeting 2016, AASLD's 67th Annual Meeting, November 11 - November 15, 2016 in Boston.

Download English Version:

<https://daneshyari.com/en/article/10217881>

Download Persian Version:

<https://daneshyari.com/article/10217881>

[Daneshyari.com](https://daneshyari.com)